AbbVie files BLA for accelerated approval of telisotuzumab vedotin for advanced NSCLC with c-Met overexpression.

AbbVie has filed a Biologics License Application with the FDA for accelerated approval of telisotuzumab vedotin (Teliso-V) for adults with previously treated, advanced non-small cell lung cancer (NSCLC) exhibiting c-Met overexpression. Supported by Phase 2 LUMINOSITY trial data, Teliso-V aims to provide a new treatment option for this underserved patient population, as there are currently no approved therapies for their condition.

September 27, 2024
5 Articles